Clinical Pharmacology & Therapeutics · 2013 · 191 citations · 2 references
MedicinePharmacologyTranslational SciencesClinical PharmacologyPharmacogeneticsPharmacogenomicsClinical Implementation Of PharmacogeneticsClinical Implementation Of PharmacogenomicsPharmacogenetic TestingPharmacogenomic TestingTranslational PharmacologyActionable Pharmacogenomic VariantsBest Practice ImplementationClinical Pharmacogenetic TestingClinical Pharmacology EvidenceClinical Translation Of PharmacogenomicsIntegration Of Pharmacogenomic Results Into Care PlansPersonalized Medicine ImplementationTranslational Pharmacogenetics
The pace of discovery of actionable pharmacogenetic variants has increased dramatically, yet implementation into individualized patient care remains slow. The PGRN Translational Pharmacogenetics Program aims to identify barriers and develop real‑world solutions for implementing evidence‑based pharmacogenetic tests in diverse health‑care settings, and to disseminate a toolbox of best practices for broad use. The program employs a real‑world implementation approach, identifying barriers and developing solutions for evidence‑based pharmacogenetic testing across diverse health‑care settings. Published in Clinical Pharmacology & Therapeutics, 2013, 94(2):207–210; doi:10.1038/clpt.2013.59.
The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of "implementation best practices" will prove useful to a broad audience. Clinical Pharmacology & Therapeutics (2013); 94 2, 207–210. doi:10.1038/clpt.2013.59
2